IRVINE , Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the Company’s fourth Phase 3 clinical trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with
PHILADELPHIA — Second Sight plans to expand the Argus II retinal prosthesis system for the treatment of retinitis pigmentosa into additional markets in the next several years, according to a speaker here.At the Wills Vision Research Center at Jefferson annual symposium, Anthony Moses, commercial vice president, Americas, at Second Sight, discussed the recent progress of the device — 3-year data results were announced in June — as well as its future market expansion.
(MedPage Today) — Implantable sterilization device may be linked to persistent pain, other adverse events
NICE, France — Sustained-release steroid implants are a successful strategy to use in well-selected patients with diabetic macular edema, taking into account potential complications. Regulatory approval by the European Medicines Agency and the FDA has clarified indications, Anat Loewenstein, MD, said at the Euretina meeting.Both Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) and Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) have proved successful in targeting the inflammatory pathway and effective in improving vision for a long period, Loewenstein said.
NICE, France — OCT angiography, or OCT-A, is a large step forward in the diagnosis, follow-up and management of age-related macular degeneration, according to Gabriel Coscas, MD. “In traditional OCT, for many years sub- or intraretinal fluid accumulation was a test of treatment efficacy to select the best schedule of intravitreal injections. Nevertheless, we know that a large number of patients remained in the group of nonresponders or partial responders in spite of multiple efforts. By directly analyzing activity criteria and blood flow in the CNV network before initial treatment and in the follow-up, OCT-A can guide us more effectively in our treatment and re-treatment decisions,” Coscas said at the Euretina meeting.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the Laden…